Semaglutide and tirzepatide were associated with better hospitalization and mortality outcomes than sitagliptin in HFpEF and type 2 diabetes.
aBritish Heart Foundation Centre of Research Excellence, School of Cardiovascular Medicine, Faculty of Life Science, King's College London, London, UK Heart failure is a complex clinical syndrome ...
19don MSN
Diabetes drug can also protect heart and liver? Doc answers as Mounjaro slashes man’s insulin by 70%
Young adults are increasingly facing type 2 diabetes risk due to stress and unhealthy habits, even if they appear thin. Doctor highlights this alarming trend. A breakthrough drug, Mounjaro, is showing ...
The benefit of beta-blockers after myocardial infarction in patients with a preserved left ventricular ejection fraction (LVEF) is unclear. We conducted a meta-analysis at the individual-patient level ...
A scientific statement has been published by the ESC regarding HFpEF in patients with cancer and cancer survivors. A new scientific statement emphasizes the importance of managing heart failure with ...
Use of semaglutide and tirzepatide, compared with sitagliptin, were associated with lower risks for heart failure hospitalization and mortality in HFpEF and type 2 diabetes. Use of semaglutide and ...
Zepbound (tirzepatide) and Wegovy (semaglutide) are FDA-approved injectable medications revolutionizing weight management. Both belong to the incretin mimetic drug class but differ in their mechanisms ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback